2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatients
2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology 2019, 20: 636-648. PMID: 30948273, DOI: 10.1016/s1470-2045(19)30029-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBRCA1 ProteinBRCA2 ProteinCanadaCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsFemaleHumansIndazolesMiddle AgedMutationOvarian NeoplasmsPeritoneal NeoplasmsPiperidinesPoly(ADP-ribose) Polymerase InhibitorsProgression-Free SurvivalTime FactorsUnited StatesYoung AdultConceptsProportion of patientsOvarian cancerAdverse eventsOverall survivalBRCA mutationsCommon treatment-emergent serious adverse eventsCommon drug-related grade 3Treatment-emergent serious adverse eventsWorse treatment-emergent adverse eventsDrug-related grade 3Last platinum-based therapyLater-line treatment optionTreatment-emergent adverse eventsLater-line treatmentPrevious chemotherapy regimensPrimary efficacy populationMedian overall survivalPlatinum-sensitive diseasePrimary peritoneal cancerSerious adverse eventsThird-line therapyLines of therapyNew safety signalsPhase 2 studyPhase 2 trial